Dominik Šafčák

Dr. Dominik Šafčák


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2020 in International Journal of Public Health
Verified
Journal Article
Closed access
PDF file
EGEastern Slovakia PBC Group
Eastern Slovakia PBC Group
SDSylvia Dražilová
Sylvia Dražilová
IBIngrid Babinská
Ingrid Babinská
JGJakub Gazda
Jakub Gazda
MHMonika Halánová
Monika Halánová
Peter JarcuskaPeter Jarcuska
Peter Jarcuska

SDSylvia Drazilova
Sylvia Drazilova
PKPavol Kristian
Pavol Kristian
MJMartin Janicko
Martin Janicko
MHMonika Halánová
Monika Halánová
DŠDominik Šafčák
Dominik Šafčák
HTHepaMeta Team
HepaMeta Team
Background: The aim of our work is to objectify the manner of transmission of HBV infection in young adult and middle-aged Roma people who live in the settlements. Methods: We used data from the cross-sectional study HepaMeta. We analyzed Roma people living in the settlements in East Slovakia, who have had HBsAg and anti HBc IgG antibodies examined. Results: We analyzed a cohort of 452 Roma participants with a mean of age 34.67 ± 9.14 years—159 (35.2%) were males. HBsAg positivity was diagnosed in 12.4% and the presence of anti HBc IgG antibodies was confirmed in 52% of participants. Prevalence of HBsAg positivity increases significantly with higher age, (p = 0.026), as well as the presence of anti HBc IgG antibodies (p < 0.0001). The prevalence of HBsAg positivity has doubled and anti HBc IgG positivity has tripled within two decades (<25 years vs. 35–45 years) in Roma settlements in East Slovakia. Conclusions: These findings allow us to express an opinion that horizontal transmission in adulthood may play an important role in the spreading of HBV infection.

22 March 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
DŠDominik Šafčák
Dominik Šafčák
SDSylvia Dražilová
Sylvia Dražilová
JGJakub Gazda
Jakub Gazda
IAIgor Andrašina
Igor Andrašina
SASvetlana Adamcova-Selcanova
Svetlana Adamcova-Selcanova
Peter JarcuskaPeter Jarcuska
Peter Jarcuska
Hepatocellular carcinoma (HCC) has multiple molecular classes that are associated with distinct etiologies and, besides particular molecular characteristics, that also differ in clinical aspects. We aim to characterize the clinical aspects of alcoholic liver disease-related HCC by a retrospective observational study that included all consequent patients diagnosed with MRI or histologically verified HCC in participating centers from 2010 to 2016. A total of 429 patients were included in the analysis, of which 412 patients (96%) had cirrhosis at the time of diagnosis. The most common etiologies were alcoholic liver disease (ALD) (48.3%), chronic hepatitis C (14.9%), NAFLD (12.6%), and chronic hepatitis B (10%). Patients with ALD-related HCC were more commonly males, more commonly had cirrhosis that was in more advanced stages, and had poorer performance status. Despite these results, no differences were observed in the overall (median 8.1 vs. 8.5 months) and progression-free survival (median 4.9 vs. 5.7 months). ALD-HCC patients within BCLC stage 0–A less frequently received potentially curative treatment as compared to the control HCC patients (62.2% vs. 87.5%, p = 0.017); and in patients with ALD-HCC liver function (MELD score) seemed to have a stronger influence on the prognosis compared to the control group HCC. Systemic inflammatory indexes were strongly associated with survival in the whole cohort. In conclusion, alcoholic liver disease is the most common cause of hepatocellular carcinoma in Slovakia, accounting for almost 50% of cases; and patients with ALD-related HCC more commonly had cirrhosis that was in more advanced stages and had poorer performance status, although no difference in survival between ALD-related and other etiology-related HCC was observed.